Quick answer
What research models is melanotan II used in? Four families appear in the published preclinical literature: receptor-expressing cell lines (such as COS cells with cloned MC1, MC3 or MC5 receptors) for binding; pigment-cell systems (frog skin, mouse melanoma cells) for adenylate cyclase and tyrosinase readouts; neural receptor work with agonist-antagonist pairs; and rodent feeding models using central delivery with a matched antagonist (Sawyer et al., 1980; Schiöth et al., 1995; Fan et al., 1997). The MT-2 product page lists the same areas as melanocortin MC1R/MC4R receptor research, melanogenesis models and pigmentation-pathway studies. This page is a model-selection guide: what each system measures, the controls it needs, and where the evidence is thin. For laboratory research use only; see the melanotan II research overview.
Choosing a model is the first design decision, and with a multi-receptor ligand it is also the one that most affects interpretation. A pigment-cell assay and a hypothalamic feeding assay can both respond to the same compound for different receptor reasons. This guide organizes the published model systems for melanotan II (MT-2) by the question each can answer, so a researcher can match a system to a hypothesis. It is a methods catalogue, not a summary of effects, and it makes no claim of benefit. The compound is supplied for laboratory research use only; not for human consumption.
Four model families
The published systems fall into four groups. The table lists each with its typical readout and the main limitation, and the sections below expand on them.
| Model family | Example in the literature | Typical readout | Main limitation |
|---|---|---|---|
| Cloned-receptor cells | COS cells expressing MC1, MC3 or MC5 (Schiöth et al., 1995) | Radioligand binding; cAMP | Overexpression; no native signaling context |
| Pigment-cell systems | Frog skin; mouse melanoma adenylate cyclase and tyrosinase (Sawyer et al., 1980) | Melanosome dispersion; cAMP; enzyme activity | Mixed receptors; species differences |
| Antagonist-paired receptor work | Agonist MTII with antagonist SHU9119 (Fan et al., 1997) | Reversal of the agonist effect | Antagonist selectivity must be established |
| Rodent central feeding models | Four mouse hyperphagia models, intracerebroventricular delivery (Fan et al., 1997) | Food intake | Route is invasive; system-level interpretation |
The product listing frames the compound as a cyclic melanocortin-receptor agonist for MC1R/MC4R receptor research, melanogenesis models and pigmentation-pathway studies; structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 and the formula C50H69N15O9, as on the MT-2 product page.
Cloned-receptor cell lines
The cleanest system for a receptor question is a cell that expresses one cloned receptor and little else. Chhajlani and colleagues expressed a cloned human melanocortin receptor in COS-7 cells and measured binding of radiolabeled [Nle4, D-Phe7]-alpha-MSH, which was displaced by melanotropic peptides but not by beta-endorphin, a non-melanotropic peptide that served as a specificity control (Chhajlani et al., 1993). Schiöth and colleagues compared MC1, MC3 and MC5 in the same host and reported different Kd values and different rank orders of peptide potency between subtypes (Schiöth et al., 1995).
Use these systems to ask: does the compound bind subtype X, with what affinity, and does it activate cAMP production? The controls are parental cells, a reference agonist, a non-melanotropic peptide for specificity, and, for functional work, forskolin. The limit is context: overexpressed receptors in a non-native host can overstate coupling efficiency. The analysis of binding and cAMP data (saturation and competition fits, Cheng-Prusoff conversion, dose-response models) is the same as for any G protein-coupled receptor ligand.
Pigment-cell systems
The historical readouts for this peptide family come from pigment cells. The 1980 analog paper used frog skin bioassay (reversible darkening through melanosome dispersion within melanophores), activation of mouse melanoma adenylate cyclase and stimulation of mouse melanoma cell tyrosinase activity (Sawyer et al., 1980). These systems report integrated responses of melanocyte-lineage cells and are the natural setting for the product page's melanogenesis and pigmentation-pathway applications.
The strengths are sensitivity and a long comparative literature. The weaknesses are that the cells carry more than one melanocortin receptor and a web of downstream pathways, so a response cannot be assigned to a subtype without antagonists or knockdown, and that frog and mouse systems do not map automatically onto other species. Practical controls include a reference agonist such as alpha-MSH, a vehicle, a cAMP-elevating control, and a receptor-blocked arm. Because tyrosinase activity and pigment content are slow endpoints, culture time, medium and passage number should be fixed and reported.
Neural receptor work and antagonist pairing
For the central receptors, the 1997 study offers the design to follow. The authors used cyclic analogs identified as potent agonists or antagonists at neural MC3 and MC4 receptors, found that the agonist MTII inhibited feeding in four hyperphagia models, and found that SHU9119, a melanocortin antagonist described as agouti-mimetic, blocked this effect and, given alone, enhanced nocturnal feeding and fast-induced feeding (Fan et al., 1997). The paired design, agonist alone, antagonist alone and both together, allows a causal statement about receptor involvement that agonist-only experiments cannot support.
In vitro, an analogous design uses neuronal or reconstituted receptor systems with the same pairing and a Schild-type analysis. The endogenous background is described by Cone, who reviews the five receptors and the agouti antagonists and notes that agonists and antagonists are expressed in a limited number of discrete locations (Cone, 2006). That discreteness is why site of delivery and receptor distribution are central to interpreting any in vivo result.
Rodent feeding models: what they do and do not show
The mouse feeding work is the best-known in vivo use of the cyclic agonist. The abstract reports intracerebroventricular delivery in fasted C57BL/6J mice, ob/ob mice, A(Y) mice and mice given neuropeptide Y, with inhibited feeding in all four and complete blockade by SHU9119 (Fan et al., 1997). The conclusion drawn by the authors is that melanocortinergic neurons exert tonic inhibition of feeding, with chronic disruption of that signal a likely explanation of the agouti obesity syndrome.
What this does not show matters as much. It is a mouse result with central delivery, not a general statement about other species or routes, and it concerns feeding behavior, not any other physiological system. A laboratory adopting such a model needs institutional animal-care approval, appropriate group sizes, randomization and blinding of the feeding measurements, and a plan for the confounders in feeding studies (stress from handling, time of day, housing). Those requirements are why many labs prefer to settle receptor questions in cells first.
Matching the model to the question
The decision aid below pairs a research question with a first model and the control that makes the answer interpretable.
| Research question | Best first model | Essential control |
|---|---|---|
| Does MT-2 bind a given subtype, and how tightly? | Cloned-receptor cells, saturation and competition binding | Parental cells; non-melanotropic peptide for specificity |
| Does binding lead to cAMP signaling? | Same cells, cAMP accumulation | Reference agonist; forskolin |
| Which subtype mediates a pigment-cell response? | Melanoma or melanocyte culture with receptor-blocking arms | Selective antagonist; knockdown if available |
| Is a central effect receptor-dependent? | Rodent model with paired agonist and antagonist | Antagonist-alone and vehicle groups |
| How does a new batch compare with an old one? | Binding or cAMP in one standard cell line | Reference lot run on the same plate |
Whatever the model, the material needs to be documented: record the lot, reconstitution details and storage; see how to reconstitute a lyophilized peptide, reconstitution volume calculations and the calculator. The product page lists a 10 mg lyophilized powder of at least 98% HPLC purity, stored at 2–8 °C or −20 °C long term, with the COA marked as coming soon; the COA page explains what documentation to look for. Compare with the structurally related PT-141 in PT-141 versus melanotan II, or browse the shop.
Cross-model pitfalls and reporting
Several problems recur whatever the system. Nomenclature drift: older papers number receptors differently from current MC1R-MC5R usage, so match receptors by tissue and ligand profile when comparing across decades. Reference compounds: the 1980 analog [Nle4, D-Phe7]-alpha-MSH became the standard radioligand and reference agonist precisely because it is potent and enzyme-resistant (Sawyer et al., 1980), but a reference is a comparison point, not a guarantee that two systems will agree. Concentration accuracy: an IC50 or EC50 is only as accurate as the stock, so calculate with the formulas in the calculator guide and record the lot.
Hadley and Dorr's review describes the design of several superpotent, prolonged-acting, enzymatically resistant analogs to clarify the role of melanocortins and their receptors in physiological function (Hadley and Dorr, 2006); that intent, a tool for clarifying receptor biology, is the one this page adopts. A minimal reporting set for any of the models above is: species and cell line with passage range; receptor subtype and expression evidence; compound lot and form; solvent, stock concentration and holding time; assay buffer and temperature; reference agonist and antagonist; number of independent experiments; and the statistical method used to fit curves. Reporting these items lets another lab reproduce or reasonably dispute a finding, which is the purpose of a model-selection exercise in the first place.
Frequently asked questions
What cell systems are used for melanotan II research?
Receptor-expressing lines such as COS cells (Chhajlani et al., 1993; Schiöth et al., 1995) and pigment-cell systems such as mouse melanoma cells (Sawyer et al., 1980).
Which readouts are standard?
Radioligand binding, cAMP or adenylate cyclase activity, tyrosinase activity and melanosome dispersion.
Why use an antagonist in the experiment?
To show the effect is receptor-mediated: reversal by a selective antagonist such as SHU9119 supports attribution (Fan et al., 1997).
What did the 1997 mouse study report?
Intracerebroventricular MTII inhibited feeding in four hyperphagia models, and SHU9119 blocked the inhibition.
Why is a parental cell control needed?
Host cells may express endogenous receptors that contribute to signal.
Can a pigment-cell response be assigned to one receptor?
Not without antagonists or knockdown, because melanocyte-lineage cells carry more than one receptor.
What is a specificity control in binding work?
A non-melanotropic peptide, such as beta-endorphin in the 1993 study, that should not displace the radioligand.
Are mouse results applicable to other species?
Not automatically; the cited work is in mice and cell systems.
What does the product page list as applications?
MC1R/MC4R receptor research, melanogenesis models and pigmentation-pathway studies.
Where should a first-time lab start?
With cloned-receptor binding and cAMP assays, which are the most controlled and cheapest to replicate.
Responsible research use
Everything on this page is offered for laboratory research use only; it is background reading for qualified researchers, not guidance for any use outside a research setting, and nothing here is a claim about benefit in people or animals. Products from V8 Peptides are sold strictly as research materials: not a drug, food or cosmetic, and not for human or animal consumption. Published studies described here were run by their authors under their own approvals and protocols, and this page does not recommend repeating them.
Related reading: Melanotan II Storage: Temperature, Moisture and Light, Melanotan II Structure: Lactam Ring and Synthesis, Melanotan II History: From alpha-MSH to Receptor Cloning.
References
- Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
- Chhajlani V, Muceniece R, Wikberg JES. Molecular cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun. 1993;195(2):866-873. doi:10.1006/bbrc.1993.2125
- Schiöth HB, Muceniece R, Wikberg JES, Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995;288(3):311-317. doi:10.1016/0922-4106(95)90043-8
- Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168. doi:10.1038/385165a0
- Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749. doi:10.1210/er.2006-0034
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029
